Literature DB >> 17547840

Dyslipidemia in type 2 diabetes mellitus.

Ramprasad Gadi, Frederick F Samaha.   

Abstract

Cardiovascular disease is a significant cause of morbidity and mortality in patients with diabetes mellitus (DM). DM is now recognized as a risk equivalent for coronary heart disease. The lipid profile in patients with type 2 DM is characterized by elevated triglycerides, low levels of high-density lipoprotein cholesterol, and small dense low-density lipoprotein cholesterol (LDLC) particles and is believed to be a key factor promoting atherosclerosis in these patients. Both primary and secondary prevention studies have provided ample evidence that aggressive statin therapy reduces cardiovascular end points in patients with DM. In all persons with DM, current treatment guidelines recommend reduction of LDLC to less than 100 mg/dL, regardless of baseline lipid levels. Lowering LDLC to less than 70 mg/dL may provide even greater benefits, particularly in very high risk patients with DM and coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547840     DOI: 10.1007/s11892-007-0036-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  34 in total

Review 1.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  Standards of medical care in diabetes--2006.

Authors: 
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

Review 3.  Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.

Authors:  P J Palumbo
Journal:  J Diabetes Complications       Date:  1998 Mar-Apr       Impact factor: 2.852

4.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

Authors:  S M Haffner; M P Stern; H P Hazuda; B D Mitchell; J K Patterson
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

5.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

Review 6.  Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.

Authors:  Eli V Gelfand; Christopher P Cannon
Journal:  J Am Coll Cardiol       Date:  2006-04-24       Impact factor: 24.094

7.  Mechanistic studies on metabolic interactions between gemfibrozil and statins.

Authors:  Thomayant Prueksaritanont; Jamie J Zhao; Bennett Ma; Brad A Roadcap; Cuyue Tang; Yue Qiu; Lida Liu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Authors:  Anthony Keech; David Colquhoun; James Best; Adrienne Kirby; R John Simes; David Hunt; Wendy Hague; Elaine Beller; Manjula Arulchelvam; Jennifer Baker; Andrew Tonkin
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

9.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

10.  Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.

Authors:  J Yuan; M Y Tsai; D B Hunninghake
Journal:  Atherosclerosis       Date:  1994-09-30       Impact factor: 5.162

View more
  14 in total

1.  Personalized medicine for diabetes.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2008-05

Review 2.  Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review.

Authors:  Parvin Mirmiran; Zahra Bahadoran; Fereidoun Azizi
Journal:  World J Diabetes       Date:  2014-06-15

3.  The interaction between apolipoprotein B insertion/deletion polymorphism and macronutrient intake on lipid profile and serum leptin and ghrelin levels in type 2 diabetes mellitus patients.

Authors:  Masoumeh Rafiee; Gity Sotoudeh; Mahmoud Djalali; Ehsan Alvandi; Mohammadreza Eshraghian; Fatemeh Javadi; Farideh Doostan; Fariba Koohdani
Journal:  Eur J Nutr       Date:  2018-01-27       Impact factor: 5.614

4.  Cardioprotective role of insulin: Advantage analogues.

Authors:  Rituparna Maiti; Jyothirmai Jaida; Pulukuri John Israel Leander; Mohammed Irfanuddin; Idris Ahmed; Anuradha Palani
Journal:  J Res Med Sci       Date:  2012-07       Impact factor: 1.852

5.  Centella asiatica enhances hepatic antioxidant status and regulates hepatic inflammatory cytokines in type 2 diabetic rats.

Authors:  Ayodeji B Oyenihi; Novel N Chegou; Oluwafemi O Oguntibeju; Bubuya Masola
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

6.  Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report.

Authors:  Patricia V Torres-Duran; Aldo Ferreira-Hermosillo; Marco A Juarez-Oropeza
Journal:  Lipids Health Dis       Date:  2007-11-26       Impact factor: 3.876

7.  Anti-hyperglycemic activity of Centella asiatica is partly mediated by carbohydrase inhibition and glucose-fiber binding.

Authors:  Ashraf Ul Kabir; Mehdi Bin Samad; Ninadh Malrina D'Costa; Farjana Akhter; Arif Ahmed; J M A Hannan
Journal:  BMC Complement Altern Med       Date:  2014-01-18       Impact factor: 3.659

8.  Lipid profile abnormalities seen in T2DM patients in primary healthcare in Turkey: a cross-sectional study.

Authors:  Aclan Ozder
Journal:  Lipids Health Dis       Date:  2014-12-06       Impact factor: 3.876

9.  Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes.

Authors:  Yijun Li; Yiming Mu; Qiuhe Ji; Qin Huang; Hongyu Kuang; Linong Ji; Xilin Yang
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

10.  In vitro antioxidant effects of Aloe barbadensis Miller extracts and the potential role of these extracts as antidiabetic and antilipidemic agents on streptozotocin-induced type 2 diabetic model rats.

Authors:  Mohammed Moniruzzaman; Begum Rokeya; Sohel Ahmed; Amrita Bhowmik; Md Ibrahim Khalil; Siew Hua Gan
Journal:  Molecules       Date:  2012-11-01       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.